



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## EDITORIAL NOTE

## COVID-19 and cardiovascular comorbidities: An update

### COVID-19 e comorbilidades cardiovasculares: uma atualização



On December 8, 2019, a case of pneumonia of unknown etiology was detected in Wuhan city, Hubei province, China.<sup>1</sup> On December 31, China reported a cluster of cases of pneumonia with unknown etiology to the World Health Organization (WHO), and seven days later, Chinese scientists identified the pathogen as a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<sup>1</sup> The WHO declared the outbreak a pandemic on 11 March 2020, due to the increasing number of cases outside China.<sup>2</sup> The pandemic is spreading exponentially, with millions of people across the globe at risk of contracting coronavirus disease 2019 (COVID-19).

Since January 2020 various series of COVID-19 patients have been published from China,<sup>3–6</sup> Italy<sup>7</sup> and the US.<sup>8</sup> Most reports have focused on COVID-19 patients admitted to the hospital, in intensive care or in wards. The series, as expected, differ in terms of demographics, the definition of comorbidities such as chronic cardiovascular disease, and clinical outcomes. Nevertheless, some observations can be made regarding the interaction between cardiovascular comorbidities and COVID-19 infection.

Hypertension, diabetes, and cardiovascular disease were the most frequent comorbidities in infected patients requiring hospitalization, compared to other chronic diseases such as cancer, chronic kidney disease and even chronic obstructive pulmonary disease. In a meta-analysis that included six Chinese studies and 1527 COVID-19 patients, the overall prevalence of hypertension, cardiovascular and cerebrovascular disease, and diabetes were 17.1%, 16.4% and 9.7%, respectively.<sup>9</sup> More recent studies from Italy<sup>7</sup> and the US<sup>8</sup> which included older patients, the majority of whom were male, report higher proportions of hypertension (over 50%) and diabetes (25%) among COVID-19 patients, which is similar to the last coronavirus pandemic, Middle East respiratory syndrome (MERS), which mainly affected the Arabian Peninsula. A systematic analysis of 637 MERS cases showed that the prevalence of hypertension and diabetes was over 50% and cardiac diseases were present in 30% of cases.<sup>10</sup>

Consistently, the severity of the disease and case fatality rates have tended to be higher in COVID-19 patients with cardiovascular comorbidities. Another recent pooled analysis showed that hypertension and a history of cardiovascular disease conferred a 2.4 (95% confidence interval [CI] 1.5–3.8) and 3.4 (95% CI 1.9–6.2) times higher risk of severe COVID-19 disease, respectively.<sup>11</sup>

The exact mechanisms underlying the worse prognosis of hypertensive COVID-19 patients remain unknown. One current hypothesis is that the excessive activation of the renin-angiotensin system (RAS) typical of the hypertensive patient may contribute to the progression of COVID-19 lung injury by promoting an inflammatory response (cytokine storm), smooth muscle cell contraction and vasoconstriction.<sup>12</sup> Moreover, some authors speculate that the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), commonly used to treat patients with cardiovascular disease, could explain their worse outcomes.<sup>13</sup> In animal studies, ACEIs/ARBs increase the expression of angiotensin-converting enzyme 2 (ACE2), the receptor which SARS-CoV-2 uses for viral entry and propagation in host cells.<sup>14</sup> On the other hand, the upregulation of ACE2 expression by ACEIs/ARBs may mitigate the deleterious ACE2 downregulation associated with COVID-19 infection, conferring pulmonary (and cardiac) protection.<sup>15</sup>

At the beginning of the pandemic, all published guidelines recommended continuing ACEIs/ARBs in patients with COVID-19.<sup>14</sup> In a recently published retrospective analysis of 1128 adult patients with hypertension diagnosed with COVID-19 from Hubei province, the use of ACEIs or ARBs was associated with a lower risk of both non-adjusted and adjusted all-cause mortality.<sup>16</sup> Two randomized phase II clinical trials in outpatient (ClinicalTrials.gov identifier: NCT04311177) and inpatient (ClinicalTrials.gov identifier: NCT04312009) settings are currently being planned to study the effect of losartan in the context of COVID-19 infection.<sup>14</sup>

<https://doi.org/10.1016/j.repc.2020.06.013>

0870-2551/© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

At the end of March 2020, the Centers for Disease Control and Prevention (CDC) reported data on underlying health conditions in COVID-19 patients in the US.<sup>17</sup> Among 122 653 US COVID-19 cases, 7162 (5.8%) patients had data available on underlying health conditions and other potential risk factors for severe outcomes from respiratory infections, and similarly to other series, a higher proportion of patients with comorbidities were admitted to the hospital and to intensive care. On the other hand, the prevalence of common clinical conditions in the US is similar to that described in this CDC report. For example, in 2018 the prevalence of diabetes among US adults was 10.1%, similar to the COVID-19 patients (10.9%). Regarding all types of heart disease (excluding hypertension), the US prevalence in 2017 was 10.6%, comparable to that observed in the CDC data, and the findings are similar regarding chronic obstructive pulmonary disease and asthma.<sup>17</sup> Moreover, data from China are also in agreement: according to the Summary of the 2018 Report on Cardiovascular Diseases in China, the prevalence of hypertension and diabetes was 23.2% and 10.9%, respectively, which is in line with the above-mentioned pooled prevalence.<sup>18</sup>

In summary, a higher prevalence of hypertension, diabetes, and chronic heart disease compared to other chronic conditions has been reported among COVID-19 patients. The prevalence of these comorbidities may nevertheless be similar to that in the general population, and these patients may not be more susceptible to COVID-19 infection. Hypertension can function as a proxy for older age and cardiovascular and non-cardiovascular comorbidities, and hence for the association in these patients with more aggressive COVID-19 disease. There is no evidence to support the idea that ACEIs or ARBs could be harmful by increasing SARS-CoV-2 infectivity. It is as yet unknown whether the severity or level of control of underlying health conditions affects the risk for severe disease in COVID-19. Nonetheless, given the limited data and potential hazard to individual and public health, a precautionary approach should be followed by carefully protecting from infection and more closely monitoring patients with multiple comorbidities, in particular those with hypertension and cardiovascular disease.

## References

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020; 323.
2. WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020; Published March 11, 2020. Accessed March 30 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020>. No Title.
3. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497–506.
5. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020.
6. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395: 507–13.
7. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020, <http://dx.doi.org/10.1001/jama.2020.5394> [Epub ahead of print].
8. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York City. *N Engl J Med*. 2020, <http://dx.doi.org/10.1056/NEJMc2010419> [Epub ahead of print].
9. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol*. 2020;109:531–8.
10. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis*. 2016;49: 129–33.
11. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Infect Dis*. 2020;94:91–5 [Epub ahead of print].
12. Sommerstein R, Kochen MM, Messerli FH, et al. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? *J Am Heart Assoc*. 2020;9:e016509 [Epub 2020 April 1].
13. Lia Y, Cheng X, Zeng Q, et al. Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province. *J Clin Cardiol*. 2020:201–3.
14. Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. *JAMA Cardiol*. 2020, <http://dx.doi.org/10.1001/jamacardio.2020.1282> [Epub ahead of print].
15. Kreutz R, Algharably EAE-H, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. *Cardiovasc Res*. 2020, <http://dx.doi.org/10.1093/cvr/cvaa097>, pii:cvaa097 [Epub ahead of print].
16. Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. *Circ Res*. 2020, <http://dx.doi.org/10.1161/CIRCRESAHA.120.317134> [Epub ahead of print].
17. Chow N, Fleming-Dutra K, Gierke R, et al., CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 382–6.
18. Ma L-Y, Chen W-W, Gao R-L, et al. China cardiovascular diseases report 2018: an updated summary. *J Geriatr Cardiol*. 2020;17:1–8.

Rogério Teixeira<sup>a,b,\*</sup>, Mário Santos<sup>c,d</sup>, Victor Gil<sup>e,f</sup>

<sup>a</sup> Serviço de Cardiologia, Hospital Geral, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

<sup>b</sup> *Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal*

<sup>c</sup> *Serviço de Cardiologia, Hospital Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal*

<sup>d</sup> *Faculdade de Medicina da Universidade do Porto, Porto, Portugal*

<sup>e</sup> *Centro Cardiovascular, Hospital dos Lusíadas, Lisboa, Portugal*

<sup>f</sup> *Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal*

\* Corresponding author.

E-mail address: [rogeriopteixeira@gmail.com](mailto:rogeriopteixeira@gmail.com) (R. Teixeira).